Portage Biotech Inc Financials
This page shows Portage Biotech Inc (PRTG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2018 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Portage Biotech Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
With a current ratio of 59.97, Portage Biotech Inc holds $59.97 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Portage Biotech Inc earns a strong 1286.4% return on equity (ROE), meaning it generates $1286 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 27.4% the prior year.
For every $1 of reported earnings, Portage Biotech Inc generates $-0.01 in operating cash flow (-$1.1M OCF vs $123.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Portage Biotech Inc reported $123.7M in net income in fiscal year 2018. This represents an increase of 659.2% from the prior year.
Portage Biotech Inc earned $0.46 per diluted share (EPS) in fiscal year 2018. This represents an increase of 666.7% from the prior year.
Cash & Balance Sheet
Portage Biotech Inc held $7.5M in cash against $0 in long-term debt as of fiscal year 2018.
Portage Biotech Inc had 281M shares outstanding in fiscal year 2018. This represents an increase of 7.7% from the prior year.
Margins & Returns
Portage Biotech Inc's ROE was 1286.4% in fiscal year 2018, measuring profit generated per dollar of shareholder equity. This is up 1259.1 percentage points from the prior year.
Capital Allocation
PRTG Income Statement
| Metric | Q4'18 | Q4'17 |
|---|---|---|
| Revenue | N/A | N/A |
| Cost of Revenue | N/A | N/A |
| Gross Profit | N/A | N/A |
| R&D Expenses | N/A | N/A |
| SG&A Expenses | N/A | N/A |
| Operating Income | N/A | N/A |
| Interest Expense | N/A | N/A |
| Income Tax | N/A | N/A |
| Net Income | N/A | N/A |
| EPS (Diluted) | N/A | N/A |
PRTG Balance Sheet
| Metric | Q4'18 | Q4'17 |
|---|---|---|
| Total Assets | N/A | N/A |
| Current Assets | $7.6M-87.1% | $59.1M |
| Cash & Equivalents | $7.5M+4629.6% | $159K |
| Inventory | N/A | N/A |
| Accounts Receivable | N/A | N/A |
| Goodwill | N/A | N/A |
| Total Liabilities | N/A | N/A |
| Current Liabilities | $127K+16.5% | $109K |
| Long-Term Debt | N/A | N/A |
| Total Equity | $9.6M-83.9% | $59.6M |
| Retained Earnings | -$14.3M-195.7% | $15.0M |
PRTG Cash Flow Statement
| Metric | Q4'18 | Q4'17 |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Investing Cash Flow | N/A | N/A |
| Financing Cash Flow | N/A | N/A |
| Dividends Paid | N/A | N/A |
| Share Buybacks | N/A | N/A |
PRTG Financial Ratios
| Metric | Q4'18 | Q4'17 |
|---|---|---|
| Gross Margin | N/A | N/A |
| Operating Margin | N/A | N/A |
| Net Margin | N/A | N/A |
| Return on Equity | N/A | N/A |
| Return on Assets | N/A | N/A |
| Current Ratio | 59.97-482.6 | 542.53 |
| Debt-to-Equity | N/A | N/A |
| FCF Margin | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Portage Biotech Inc profitable?
Yes, Portage Biotech Inc (PRTG) reported a net income of $123.7M in fiscal year 2018.
What is Portage Biotech Inc's return on equity (ROE)?
Portage Biotech Inc (PRTG) has a return on equity of 1286.4% for fiscal year 2018, measuring how efficiently the company generates profit from shareholder equity.
What is Portage Biotech Inc's operating cash flow?
Portage Biotech Inc (PRTG) generated -$1.1M in operating cash flow during fiscal year 2018, representing cash generated from core business activities.
What is Portage Biotech Inc's current ratio?
Portage Biotech Inc (PRTG) had a current ratio of 59.97 as of fiscal year 2018, which is generally considered healthy.
What is Portage Biotech Inc's cash runway?
Based on fiscal year 2018 data, Portage Biotech Inc (PRTG) had $7.5M in cash against an annual operating cash burn of $1.1M. This gives an estimated cash runway of approximately 84 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Are Portage Biotech Inc's earnings high quality?
Portage Biotech Inc (PRTG) has an earnings quality ratio of -0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Portage Biotech Inc?
Portage Biotech Inc (PRTG) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.